Dainippon Sumitomo Pharma builds new chemistry research center
Started in January 2012, construction cost of the new facility was nearly JPY6.4bn ($64.3m) and is expected to be fully operational in July 2013. The new facility will
Started in January 2012, construction cost of the new facility was nearly JPY6.4bn ($64.3m) and is expected to be fully operational in July 2013. The new facility will
Investigational recombinant analog of the human hormone leptin, Metreleptin is being assessed for the treatment of metabolic disorders coupled with inherited or acquired lipodystrophy. Bristol-Myers CV and Metabolics
Aimed at advancing the company’s first clinical candidate into preclinical studies, the three-year grant will particularly support non-human primate efficacy studies, mechanism of action experiments, and discovery of
Therapeutically equivalent to Depo-Testosterone Injection of Pfizer, the Testosterone Cypionate Injection USP, 100 mg/mL and 200mg/mL is indicated for males with deficiency or absence of endogenous testosterone. The
Featuring PerkinElmer’s Flick-to-Share technology, both ChemDraw and Chem3D apps will enable scientists to collaborate and share critical information in real-time in and out of the laboratory. PerkinElmer vice
Under the contract, early stage proof-of-concept feasibility process development will be conducted to identify concentrating AVA filtrate for storage before the downstream process for vaccine. GBI process development
The world’s first FD treatment, Acofide demonstrated efficacy in FD patients diagnosed by the international diagnostic criteria for functional gastrointestinal diseases, the Rome III. Both the companies will
Under the agreement, a whole genome mapping module was incorporated by Applied Maths into the company’s new BioNumerics 7 software suite. With the new software tool, customers can
MOR103 has concluded Phase 1/2 development in mild to moderate rheumatoid arthritis. As per the terms of the agreement, MorphoSys will receive from GSK $29.3m (€22.5m) as immediate
Acadia CEO Uli Hacksell said that the molecule has demonstrated an attractive profile and has distinctly different properties from other glaucoma compounds advanced under the collaboration. Both the